SAN DIEGO — October 16, 2025 — Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is proud to announce that it has been named Best Preclinical Oncology CRO 2025 in the Healthcare and Pharmaceutical Awards by Global Health and Pharma (GHP) Magazine.
Now in its tenth year, the Healthcare and Pharmaceutical Awards program celebrates organizations driving innovation and excellence across the life sciences industry. Crown Bioscience received this recognition for its outstanding contributions to preclinical oncology research and its comprehensive portfolio of translational platforms that help biopharmaceutical partners accelerate drug discovery and development.
With 11 global facilities and 20 years of scientific expertise, Crown Bioscience provides a unique combination of high-quality patient-derived xenograft (PDX) models, tumor organoid platforms, and immuno-oncology services – including one of the world’s largest commercially available PDX collections. The company’s innovative preclinical solutions continue to set new standards in translational science, enabling customers to make more informed decisions and bring life-changing therapies to patients faster.
For the full list of winners, visit GHP Magazine’s announcement page. To learn more about Crown Bioscience’s industry awards and recognitions, click here.
Media Inquiries:
Crown Bioscience
Sarah Martin-Tyrrell
pr@crownbio.com
